Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI

Current share price for NTI : $0.013 -0.003 (-16.67%)⁺

Announcement

Appendix 4E & Annual Report to shareholders

Release

26 Aug 2026 5:19PM

Price at Release

$0.015

Full Release

Summary

Neurotech International Limited's 2026 Annual Report highlights its focus on developing NTI164, a cannabinoid therapy for paediatric neurological disorders, specifically Autism Spectrum Disorder (ASD), currently in Phase 3 trials. The company recorded a financial year loss of $6.54 million as of 30 June 2026, with no dividends declared. Key achievements include significant regulatory advancements, such as obtaining FDA designations for NTI164, while a strategic focus is directed towards its clinical development program. This includes a $4.5 million investment to support its Phase III trial and regulatory activities, bolstered by executive leadership changes and US FDA IND clearance for NTI164.

Key Points

Neurotech International Limited focused on paediatric neurological disorders with NTI164.
NTI164 is a broad-spectrum oral cannabinoid therapy in Phase 3 trials for Autism Spectrum Disorder (ASD).
The company's financial year ended 30 June 2026 with a net loss of $6.54 million.
Revenue increase attributed to R&D grant income, totaling $4.8 million.
No dividends were paid or recommended for the financial year.
Significant regulatory milestones achieved, including FDA Rare Pediatric Disease Designation for NTI164 in Rett Syndrome.
Company divested its neurofeedback device subsidiaries to focus on NTI164.
Received $4.5 million investment commitments for Phase III trial and regulatory activities.
Executive leadership changes with Mark Davies appointed as Executive Chairman.
US FDA clearance granted for Investigational New Drug (IND) submission for NTI164.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.